ViGenCell Inc. (308080.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩5,070 (+0.00%) as of
Key statistics
- Market cap
- 103.93B
- Dividend yield
- 0.00%
- 52-week range
- 3,070.00 – 17,360.00
- Beta
- 1.79
- Revenue (TTM)
- 278.95M
- Profit margin
- 0.00%
- Volume
- 82.34k
About ViGenCell Inc.
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seoul, South Korea
- Employees
- 64
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.